Phaseline

Targets › TREM1

TREM1 (Triggering receptor expressed on myeloid cells 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other.

[Isoform 1]: Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12. (UniProt, Q9NP99)

Open in Phaseline: the race on TREM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Inotremnangibotide
Triggering receptor expressed on myeloid cells 1 inhibitor
TREM1Phase 2Shock, Septic–

Conditions

Shock, Septic (1)

Modalities

protein or peptide (1)

Companies

Inotrem (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.